Claudio Lotesoriere

Castellana, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Predictive biomarkers for cetuximab-based rechallenge therapy in metastatic colorectal cancer: a pooled analysis of the CAVE and CAVE-2 GOIM studies.

Journal: ESMO gastrointestinal oncology

Published: August 28, 2026

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

HER-2 gene alterations as biomarker in patients with metastatic colorectal cancer treated with FOLFIRI + cetuximab: findings from the CAPRI-2 GOIM study.

Journal: ESMO gastrointestinal oncology

Published: April 17, 2026

Barriers and Priorities for Immunotherapy Implementation in Advanced Gastric Cancer: Findings from a Two-Phase Qualitative Study.

Barriers and Priorities for Immunotherapy Implementation in Advanced Gastric Cancer: Findings from a Two-Phase Qualitative Study.

Journal: Journal of gastrointestinal cancer

Published: January 31, 2026

Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma following gemcitabine-based therapy. A systematic review and meta-analysis of randomized controlled trials.

Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ductal adenocarcinoma following gemcitabine-based therapy. A systematic review and meta-analysis of randomized controlled trials.

Journal: Clinical & experimental metastasis

Published: January 15, 2026

Automated Pathomic Analysis of Angiogenesis and Immune Profiles Unveils an Interpretable Prognostic Biomarker in Colon and Gastric Cancers.

Automated Pathomic Analysis of Angiogenesis and Immune Profiles Unveils an Interpretable Prognostic Biomarker in Colon and Gastric Cancers.

Journal: IEEE journal of biomedical and health informatics

Published: November 24, 2025

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: November 04, 2025

Liquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs.

Liquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs.

Journal: Oncology reviews

Published: September 10, 2025

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy.

Journal: ESMO open

Published: September 07, 2025

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.

Integrating tissue and liquid biopsy comprehensive genomic profiling to predict efficacy of anti-EGFR therapies in metastatic colorectal cancer: Findings from the CAPRI-2 GOIM study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 13, 2025

Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.

Comprehensive genomic profiling by liquid biopsy in refractory metastatic colorectal cancer patients who are candidate for anti-EGFR rechallenge therapy: findings from the CAVE-2 GOIM trial.

Journal: ESMO open

Published: March 16, 2025

Pharmacometric and Digital Twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer.

Pharmacometric and Digital Twin modeling for adaptive scheduling of combination therapy in advanced gastric cancer.

Journal: Computer methods and programs in biomedicine

Published: March 10, 2025

Unravelling Paclitaxel Resistance in Gastric Cancer: The Role of Small Extracellular Vesicles in Epithelial Mesenchymal Transition and Extracellular Matrix Remodelling.

Unravelling Paclitaxel Resistance in Gastric Cancer: The Role of Small Extracellular Vesicles in Epithelial Mesenchymal Transition and Extracellular Matrix Remodelling.

Journal: Cancers

Published: February 28, 2025

Showing 1-12 of 37

Last Updated: 09/26/2026